236 related articles for article (PubMed ID: 16480425)
1. Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches.
Gille J
Exp Dermatol; 2006 Mar; 15(3):175-86. PubMed ID: 16480425
[TBL] [Abstract][Full Text] [Related]
2. Future directions in the use of antiangiogenic agents in patients with colorectal cancer.
Hoff PM
Semin Oncol; 2004 Dec; 31(6 Suppl 17):17-21. PubMed ID: 15696026
[TBL] [Abstract][Full Text] [Related]
3. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenesis agents in colorectal cancer.
Hubbard J; Grothey A
Curr Opin Oncol; 2010 Jul; 22(4):374-80. PubMed ID: 20375894
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions.
Goldberg RM; Hurwitz HI; Fuchs CS
Clin Adv Hematol Oncol; 2005 Dec; 3(12):1-10; quiz 11. PubMed ID: 16555433
[TBL] [Abstract][Full Text] [Related]
6. The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments.
Gridelli C; Maione P; Rossi A; De Marinis F
Oncologist; 2007 Oct; 12(10):1183-93. PubMed ID: 17962612
[TBL] [Abstract][Full Text] [Related]
7. Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer.
Grothey A
Semin Oncol; 2006 Oct; 33(5 Suppl 10):S41-9. PubMed ID: 17145524
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic strategies using VEGF inhibitors in colorectal cancer].
Boige V; Malka D; Ducreux M
Bull Cancer; 2005 Aug; 92(Spec no):S29-36. PubMed ID: 16387667
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms and targeting of colorectal cancer.
Vanhoefer U
Semin Oncol; 2005 Dec; 32(6 Suppl 8):7-10. PubMed ID: 16360005
[TBL] [Abstract][Full Text] [Related]
10. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Langer CJ; Natale RB
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
[TBL] [Abstract][Full Text] [Related]
11. Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies.
Reinacher-Schick A; Pohl M; Schmiegel W
Nat Clin Pract Gastroenterol Hepatol; 2008 May; 5(5):250-67. PubMed ID: 18382435
[TBL] [Abstract][Full Text] [Related]
12. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.
Los M; Roodhart JM; Voest EE
Oncologist; 2007 Apr; 12(4):443-50. PubMed ID: 17470687
[TBL] [Abstract][Full Text] [Related]
13. Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer.
Bertino EM; Otterson GA
Lung Cancer; 2010 Dec; 70(3):233-46. PubMed ID: 20888062
[TBL] [Abstract][Full Text] [Related]
14. Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer.
Socinski MA
Cancer Treat Rev; 2011 Dec; 37(8):611-7. PubMed ID: 21641723
[TBL] [Abstract][Full Text] [Related]
15. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
Wilson PM; LaBonte MJ; Lenz HJ
Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
[TBL] [Abstract][Full Text] [Related]
16. Beyond bevacizumab: antiangiogenic agents.
Rogosin S; Sandler AB
Clin Lung Cancer; 2012 Sep; 13(5):326-33. PubMed ID: 22297207
[TBL] [Abstract][Full Text] [Related]
17. [Bevacizumab. Progress in cancer therapy by antiangiogenesis].
Krämer I; Lipp HP
Med Monatsschr Pharm; 2006 Jul; 29(7):249-54; quiz 255-6. PubMed ID: 16866078
[TBL] [Abstract][Full Text] [Related]
18. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
19. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S; Rich JN
Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]